Researchers
-
Begoña Pina Marín
Ophthalmology
-
Carlos Luis Moser Würth
Ophthalmology
-
Carlos Martínez Belló
Ophthalmology
-
Diana Paola Mora Ramirez
Ophthalmology
-
Joan Josep Escobar Barranco
Ophthalmology
-
Josep Badal Lafulla
Ophthalmology
Phd -
Luis Amselem Gómez
Ophthalmology
-
Magela Garat Chifflet
Ophthalmology
-
Manel Fernández Bonet
Ophthalmology
-
Monica Lecumberri López
Ophthalmology
-
Rafael Alcubierre Bailac
Ophthalmology
-
Sabrina Bojados
Ophthalmology
-
Stephanie Carrillo
Ophthalmology
Contact the group
Form-
Wu L, Zas M, Berrocal MH, Arevalo JF, Figueroa M, Rodriguez F, Serrano M, Graue F, Alezzandrini A, Gallego-Pinazo R, Roca JA, Iglicki M, Dalma-Weishauz J, Kozak I, Collado A, Badal J, Maia M, Salcedo-Villanueva G, Quiroz-Mercado H, Fromow-Guerra J, Lozano-Rechy D, Avila M, Chhablani J. 1375
ANATOMICAL AND FUNCTIONAL OUTCOMES OF SYMPTOMATIC IDIOPATHIC VITREOMACULAR TRACTION: A Natural History Study From the Pan American Collaborative Retina Study Group.
Retina. 2016;36(10):1913-8.
-
Escobar-Barranco JJ, Pina-Marín B, Fernández-Bonet M. 1301
Dexamethasone implants in patients with naive or refractory diffuse diabetic macular edema.
Ophthalmologica. 2015;233(3-4):176-85
-
Casaroli-Marano R, Gallego-Pinazo R, Fernández-Blanco CT, Figueroa MS, Pina Marín B, Fernández-Baca Vaca G, Piñero-Bustamante A, Donate López J, García-Arumí J, Farrés Martí J. 1210
Age-Related Macular Degeneration: Clinical Findings following Treatment with Antiangiogenic Drugs.
J Ophthalmol. 2014;2014:346360
-
Mansour AM, Arevalo JF, Badal J, Moorthy RS, Shah GK, Zegarra H, Pulido JS, Charbaji A, Amselem L, Lavaque AJ, Casella A, Ahmad B, Paschall JG, Caimi A, Staurenghi G. 1204
Paraproteinemic maculopathy.
Ophthalmology. 2014;121(10):1925-32.
-
Millá E, Mañé B, Duch S, Hernan I, Borràs E, Planas E, Dias Mde S, Carballo M, Gamundi MJ; Spanish Multicenter Glaucoma Group-Spanish Multicenter Study of Glaucoma Genetic Research, EMEIGG. (Martínez Belló C) 1153
Survey of familial glaucoma shows a high incidence of cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1) mutations in non-cosanguineous forms in a Spanish population.
Molecular Vision 2013;19:1707-1722.
Projects
-
- Year 2020
- Comprehensive Care Center Dos de Maig Hospital
Multicenter Phase Iii Study, Randomized, With Double Masking, Controlled With Active Comparator, To Evaluate The Efficacy And Safety Of Faricimab In Patients With Macular Edema Secondary To Retinal Venous Branch Occlusion.
-
DISTRICT ATTORNEY:
F. Hoffmann-La Roche Ltd.
-
TYPE E:
RD2015
-
- Year 2020
- Comprehensive Care Center Dos de Maig Hospital
A phase III, multicenter, prospective, randomized, double-masked, active-comparator-controlled, two-arm study to evaluate the efficacy and safety of intravitreal KSI-301 compared with intravitreal aflibercept in naive participants with visual impairment due to macular edema secondary to retinal vein occlusion (RVO).
-
DISTRICT ATTORNEY:
Kodiak Sciences Inc.
-
TYPE E:
RD2015
-
- Year 2020
- Sant Joan Despí Moisès Broggi Hospital
Effectiveness of the boost application to predict visual quality in cataract surgery.
-
DISTRICT ATTORNEY:
Monica Lecumberri
-
TYPE E:
PINE TREE
-
- Year 2020
- Comprehensive Care Center Dos de Maig Hospital
Preliminary randomized, double-masked, 48-week, parallel-group, placebo-controlled demonstrative study to investigate the efficacy and safety of RG7774 in patients with type 1 or type 2 diabetes mellitus with previously untreated diabetic retinopathy.
-
DISTRICT ATTORNEY:
F. Hoffmann-La Roche Ltd
-
TYPE E:
RD2015
-
- Year 2020
- Sant Joan Despí Moisès Broggi Hospital
A phase III, multicenter, prospective, randomized, double-masked, active comparator-controlled, two-treatment arm study to evaluate the efficacy and safety of intravitreal KSI-301 compared with intravitreal aflibercept in naive participants with secondary visual impairment to diabetic macular edema (DMD).
-
DISTRICT ATTORNEY:
Kodiak Sciences Inc.
-
TYPE E:
RD2015
-
- Year 2020
- Sant Joan Despí Moisès Broggi Hospital
Design And Validation Of A Questionnaire For The Telematic Triage Of The First Ophthalmology Visits Derived From The Head Doctor In Primary Care Centers.
-
DISTRICT ATTORNEY:
Stephany Carrillo Cristancho
-
TYPE E:
PINE TREE
-
- Year 2020
- Comprehensive Care Center Dos de Maig Hospital
Extension, open and multicenter study to evaluate the long-term safety and tolerability of Faricimab in patients with diabetic macular edema.
-
DISTRICT ATTORNEY:
F. Hoffmann-La Roche Ltd
-
TYPE E:
RD2015
-
- Year 2020
- Comprehensive Care Center Dos de Maig Hospital
Phase IIIb/IV, open-label, single-group, 56-week extension study to evaluate the efficacy and safety of brolucizumab 6 mg in a treatment-to-control regimen with maximum treatment intervals of 20 weeks in patients with age-associated neovascular macular degeneration who have completed the CRTH258A2303 (TALON) study.
-
DISTRICT ATTORNEY:
Novartis pharmaceutical, SA
-
TYPE E:
RD2015
-
- Year 2020
- Comprehensive Care Center Dos de Maig Hospital
Retrospective observational study to evaluate the association between anatomical and clinical results in patients with neovascular age-related macular degeneration (AMD) treated with anti-VEGF in the FRB Registry!.
-
DISTRICT ATTORNEY:
CLINICAL FOUNDATION FOR BIOMEDICAL RESEARCH
-
TYPE E:
EPA-OD
-
- Year 2020
- Comprehensive Care Center Dos de Maig Hospital
Phase III, multicenter, randomized, double-masked and parallel-group study to compare the efficacy, safety, tolerability, pharmacokinetics and immunogenicity of SCD411 and Eylea® in subjects with age-related neovascular macular degeneration.
-
DISTRICT ATTORNEY:
SCD (SamChunDang Pharm. Co.,Ltd)
-
TYPE E:
RD2015
Lines of action
- Treatment of retinal diseases with intravitreal medication
- Anti VEGF in diabetic macular edema
- Anti VEGF in central serous chorioretinopathy
- Treatment of Diabetic Retinopathy
- UTI (Intravitreal Therapy Unit)
- New techniques in cataract surgery
- Surgical alternatives to full thickness corneal transplantation
- Microkeratum assisted keratoplasty Anterior and posterior lamellar techniques
